Objectives: Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD).
Conclusion: Clopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD.
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| I N TR ODU C TI ON
Peripheral arterial disease (PAD) is a major complication of atherosclerosis and is an important aspect of cardiovascular disease. Class 1 recommendation from the American Heart Association and American College of Cardiology management guidelines for PAD patients include the use of antiplatelet agents such as aspirin, with clopidogrel as a reasonable alternative [1] [2] [3] .
However, there is wide variability in patients' responses to aspirin and clopidogrel and other thienopyridines, resulting in the concept of aspirin and clopidogrel "high on-treatment platelet reactivity" (HoTPR) or "non-responsiveness" or "resistance" [4, 5] . Aspirin and clopidogrel HoTPR has been correlated with adverse clinical cardiovascular outcomes in coronary artery disease patients [5] [6] [7] [8] , although this factor has been less well examined in patients with PAD. Multiple genetic polymorphisms have been associated with aspirin and clopidogrel HoTPR. However, these have largely been in coronary artery disease literature [9] [10] [11] [12] . In the PAD arena, Karnabatidis et al. showed that clopidogrel HoTPR prevalence to be as high as 51% in a cohort of PAD patients. From the same group, Spiliopoulus showed in the PRECLOP study that clopidogrel HoTPR was the only significant predictor of adverse clinical events in a prospective cohort of 100 patients undergoing infrainguinal angioplasty or stenting. In the PRECLOP study, the one-year cumulative event rate was as high as 52% and 84% in the third and fourth quartiles of clopidogrel HoTPR. Despite these findings, significant gaps of knowledge remain for patients with PAD. Accordingly, the aims of this study are to determine the prevalence of aspirin and clopidogrel HoTPR in a cohort of treated patients with PAD and determine their association with candidate genetic markers, as well as associated adverse cardiovascular outcomes. gov; with identification number NCT03174990. Inclusion criteria consisted of male and female patients older than 18 years of age undergoing diagnostic angiography (carotid and lower extremity) or therapeutic intervention (surgical or endovascular) for PAD. Exclusion criteria included (1) patients who were unable to take aspirin AND clopidogrel for any reason; (2) platelet count < 100 K; hematocrit <30% or >52% (limitations of the VerifyNow assay); (3) patients taking warfarin, ticlopidine, prasugrel, or ticagrelor were excluded from the study.
| M E TH ODS
Patients were treated according to operator preference but DAPT was required for a minimum of 30 days if a percutaneous intervention was performed. Continued DAPT beyond one month was at the discretion of the operator. The inclusion criteria did not necessitate that patients had to be on DAPT prior to enrolment. We had enrolled patients if they required angiographic evaluation for PAD. However, in some patients, if intervention was not performed or if surgery was performed instead, they would not be on DAPT. The protocol did not further consider the role of any revascularization in its analysis.
Whole blood samples were obtained from each patient via standard venipuncture. Aspirin and clopidogrel HoTPR was tested using the VerifyNow Assay (Accriva Diagnostics, San Diego, CA). For the clopidogrel HoTPR test, the subject had to be on clopidogrel for at least five days. If the subject was naïve to clopidogrel, the test was performed 5-7 hr after a loading dose of 300-600 mg. Patients would be loaded with aspirin 300 mg if they were not already on aspirin. Blood testing for HoTPR for both drugs would be done at the time of clopidrogel HoTPR testing. Blood samples may be obtained any time if a patient was on chronic aspirin and clopidogrel treatment. Aspirin HoTPR was defined as patients with aspirin reaction units (ARU) 550 [13] . Clopidogrel HoTPR was defined as patients with P2Y12 reaction units (PRU) 235 [6] . The rest of the blood was frozen and retained for genetic analysis.
All patients and investigators were blinded to the test results.
Major adverse cardiovascular events (stroke, myocardial, and all-cause mortality), limb loss and target vessel revascularization (TVR) at six months and one year were collected using chart review, clinic visits and telephone interviews. Note that TVR only applies if the vessel had been revascularized. The primary end-point was a composite of major adverse cardiovascular events at one year, including all-cause mortality, myocardial infarction, stroke, TVR, and limb loss in patients who underwent extremity intervention.
| Single nucleotide polymorphisms Analyses
Genomic DNA was extracted from whole blood specimens using Gentra Systems PUREGENE DNA Purification Kit (Qiagen). SNP were cor- glycoprotein IIb/IIIa receptor polymorphisms (e.g. PlA1 and PlA2 alleles [14] [15] [16] ); (3) platelet collagen receptors [17] , and the GPV1 receptor gene [18] ; (4) ADP receptor P2Y1-12 [19] , and (5) Factor XIII [20, 21] .
We have also included phospholipase A2 as well as other enzymes responsible for arachidonic acid metabolisms including cytochrome P450, lipoxygenase and hydrolase.
In addition, previous studies have identified polymorphisms of genes involved in clopidogrel absorption (ABCB1), metabolisms (CYP3A5 and CYP2C19) [22] , and biologic activity (P2RY1214 and ITGB311) [23, 24] . Moreover, one recent study has identified PON1 as a major determinant of clopidogrel efficacy [25] . These genes were selected for our candidate SNP analyses.
| Sample size calculations
Based on studies of high risk patients (including patients with PAD) such as described in the CHARISMA trial, the event rate for aspirin or thienopyridine responsive patients is approximately 7% over one year [26] . In our study, we included the additional outcome of TVR given the nature of the patients included. We estimated a sample size of 400 patients over two years. Assuming a prevalence of either aspirin or thienopyridine HoTPR at 25% [27] , a MACE event rate of 20% in the resistant group and 10% in the responsive group, we would have 75%
power to detect a clinically important difference at the significance level of 0.05 (95% confidence level) at one-year follow up. However, due to slow enrolment, the study was terminated upon reaching 195 patients.
| Statistical Analyses
The 
| RE S U L TS
One-hundred and ninety-five patients were enrolled between August 2010 and September 2012. Although our target enrolment target was 400 patients, due to slow recruitment rates, we were only able to recruit 195 patients. This was largely affected by patients who were
anemic and could not be tested by the VerifyNow system. The study was stopped prematurely as a result of slow patient enrolment.
Of the 195 patients, 154 were taking both aspirin and clopidogrel post-procedure. Table 1 of patients. Table 2 shows the clinical characteristics of patients with and without clopidogrel HoTPR. Table 3 shows the clinical characteristics of patients with and without aspirin HoTPR. Tables 4 and 5 show frequencies were tested for HWE using the v 2 test. All of the reported genotype distributions were in HWE (P values > 0.10).
| D I SCUSSION
Our study demonstrated that aspirin HoTPR was present in 17%-20% of patients with PAD, while clopidogrel HoTPR was present in approximately 50%. Second, it also showed that there was a statistical trend for clopidogrel HoTPR to be associated with a combined endpoint of myocardial infarction, death, stroke, amputation, or TVR while there was no significant association between aspirin HoTPR and combined outcomes. Importantly, TVR was significantly higher in those with PRU 235. Third, we demonstrate that SNP in serum PON1 gene (both heterozygous and homozygous) was associated with aspirin HoTPR (P 5 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P 5 0.002). showed that in patients with drug eluting stents, HoTPR to clopidogrel was associated with significantly higher rates of CV death (2.8% vs.
0%, P 5 0.04) and stent thrombosis (4.6% vs. 0%, P 5 0.004) [6] . The prevalence of aspirin HoTPR in PAD patients is less clear. Saunders et al. showed in a study of 80 patients that between 5% and 27.5%
were poor responders to aspirin when tested over 6-to 12-month follow-up [29] . Karnabatidis and colleagues reported in a recent study of 145 patients with PAD, also using the VerifyNow test, that the prevalence of aspirin HoTPR was 20.7%. HoTPR to clopidogrel was 50.8% while 12.5% of patients were non-responsive to both aspirin and clopidogrel [30] . The same group extended their investigations and published the PRECLOP study in 2013 [31] . In this study cohort of 100 patients, Spiliopoulous et al. showed that PRU was a prognostic indicator for the primary combined endpoint of one-year cumulative clinical events rate (composite endpoint of death, bleeding, major amputation, or clinically driven target vessel re-intervention). Interestingly, the study showed that the optimal cutoff value for the composite endpoint was PRU 234. Our findings showed surprisingly similar prevalence rates for clopidogrel and aspirin HoTPR of 50% and 20% respectively. These findings provide independent and corroborative evidence on the likely true prevalence of antiplatelet HoTPR in patients with PAD.
Mueller et al. examined 100 patients who underwent peripheral
arterial balloon angioplasty for intermittent claudication, and was able to associate clinical outcome with aspirin HoTPR [32] . In the 18-month follow-up period, the risk for arterial re-occlusion in these aspirinresistant men was 87% higher than in the aspirin-responsive group (P 5 0.009). Unlike the study by Spiliopoulous and Mueller, we were unable to demonstrate any significant association between aspirin or clopidogrel HoTPR and adverse outcomes, although there was a trend toward higher rates of the primary combined endpoint with clopidogrel alleles [14] [15] [16] ); (3) platelet collagen receptors [17] , and the GPV1 receptor gene [18] ; (4) ADP receptor P2Y1-12 [19] , and (5) Factor XIII [20, 21] . Since aspirin blocks one of the key pathways in arachidonic acid metabolism, we have also included phospholipase A2 critical for the release of arachidonic acid as well as other enzymes responsible for arachidonic acid metabolisms including cytochrome P450, lipoxygenase, and hydrolase.
In addition, previous studies have identified polymorphisms of genes involved in clopidogrel absorption (ABCB1), metabolisms (CYP3A5 and CYP2C19) [22] , and biologic activity (P2RY1214 and ITGB311) [23, 24] . Moreover, one recent study has identified PON1 as a major determinant of clopidogrel efficacy [25] . PON1 gene is located on the long arm of chromosome 7 and encodes for an enzyme hydrolase [33] . PON1 is also an anti-atherosclerotic component of highdensity lipoprotein and has been shown to be protective against the development of atherosclerosis [34] . These genes were selected for our candidate SNP analyses.
| Aspirin high on-treatment platelet reactivity
Our analyses identify SNP in serum PON1 gene (both heterozygous and homozygous) to be associated with aspirin HoTPR (P 5 0.005).
PON1 gene is located on the long arm of chromosome 7 and encodes for an enzyme hydrolase [33] . PON1 is also an anti-atherosclerotic component of high-density lipoprotein and has been shown to be protective against the development of atherosclerosis [34] . The activity of PON1 is critically affected by genetic polymorphisms [35] . Moreover, one recent study has identified PON1 as a major determinant of clopidogrel efficacy [25] . shown to be associated with an increase in the incidence of coronary artery disease and acute coronary syndrome [36] . Our findings linking genetic polymorphisms and PLA2G3 gene further support critical roles of arachidonic acid metabolisms in clopidogrel HoTPR.
| LI M I TA TI ON S
One possible limitation of this study is the use of the VerifyNow assay.
However, the test has been shown to correlate well with the 'gold standard' of light transmittance aggregometry for aspirin [37, 38] or clopidogrel HoTPR [39, 40] . Most importantly, the VerifyNow assay has been correlated in a number of recent studies to clinical outcomes [6, 8, 31, 41] . It has been shown that the clopidogrel efficacy after a loading dose may not represent exactly the effect when the steady-state phase of therapy has been achieved, therefore, it would have been ideal if the timing of testing clopidogrel responsiveness was homogenous [42, 43] . However, this was not possible to perform for logistical reasons.
Our study needs to be interpreted in the context of the premature termination of the study due to slow patient enrolment. This resulted in the relatively small sample size limiting our ability to show a statistically significant difference in outcomes between those with and without HoTPR. Although the study initially planned for more patients, slow enrolment made this difficult. The small sample size is especially relevant in terms of the genetic analysis of genotypes that demonstrate association with aspirin and/or clopidogrel HoTPR. Despite the sample size, we were able to demonstrate that clopidrogrel HoTPR was associated with TVR. Lastly, the study population included diverse PAD The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
